Skip navigation

Renasight™

Kidney gene panel

The Renasight™ test evaluates 385 genes associated with chronic kidney disease (CKD) to determine if there is a genetic cause for an individual’s kidney disease or if there is an increased hereditary risk due to family history. Renasight™ uses either blood or saliva samples and can enable improved diagnoses and personalized patient care. Results are available in approximately 3 weeks.

Discover more with Renasight™

  • NKF and KDIGO recommend genetic testing for patients with kidney disease.1,2
  • Renasight™ is a comprehensive kidney panel with 385 genes custom-designed for nephrology
  • Identify rare and common inherited conditions associated with chronic kidney disease (CKD), nephrolithiasis, and electrolyte disorders— including PKD1 and the APOL1 risk allele
  • Includes conditions associated with pediatric and adult forms of CKD
OH_REN_Clinician_s1

Meaningful utility for you and your patients

RenaCARE, a large-scale multi-site prospective study of genetic testing in CKD, demonstrates the diagnostic and clinical utility of Renasight™1

alt text
Dahl NK, Bloom MS, Chebib FT, et al. The Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults with Chronic Kidney Disease.J Am Soc Nephrol. 2023;doi:10.1681/ ASN.0000000000000249

Backed by societies, proven by research

The National Kidney Foundation (NKF) and Kidney Disease Improving Global Outcomes (KDIGO) now recommend genetic testing for the majority of patients with kidney disease.1,2 These recommendations highlight the crucial role of genetic testing and encourage broad use in Nephrology care.

NKF and KDIGO do not endorse a specific test

See additional published support for genetic testing

Enable improved diagnoses and patient care

Cancer Color Icon

Determine the underlying cause of disease where clinical features alone fell short or were previously unknown.

Functional Testing Icon

Impact treatment path by using test results to inform more tailored interventions.

Technology Icon

Detailed the subtype of a CKD diagnosis.

Services Icon

Educate family members who may also be at risk for kidney disease.

Services Icon

Eligibility for appropriate clinical trials that may provide advanced treatments and interventions.

The Renasight™ Difference

Renasight™ is the leading renal generic test. We are focused on making genetic testing comprehensive, convenient, and accessible.

Comprehensive Icon

Comprehensive

Renasight™ is a comprehensive kidney panel with 385 genes custom-designed for nephrology.

  • Selected by genetic experts to provide actionable information
Convenient Icon

Convenient

Natera provides support for providers and patients at every step.

  • Seamless remote testing services for providers and at home sample collection for patients (saliva or mobile blood draw).
  • Complimentary information sessions with board-certified genetic counselors.
  • Clear, actionable reports, served with time-saving tools and access to expert guidance.
Accessible Icon

Accessible

We are committed to making testing as affordable as possible

  • Most patients have little-to-no out of pocket cost
  • In the rare situation where the cost is above $149, we will attempt to reach out to the patient to determine if they qualify for our financial assistance programs.

Explore Case Studies

Explore and submit real-world case studies showcasing the impact of Renasight™. See how industry leaders are improving diagnoses and patient care in nephrology with Renasight™

Support for you and your patients at every step

Access to complimentary renal genetic experts and resources

Natera’s team of renal genetic counselors are trained and certified to provide the highest level of support to you and your patients

For Providers

  • Consult prior to testing to review gene panel and answer questions
  • Provide guidance on the Renasight™ test report
  • Explain how gene changes can cause genetic conditions
  • Inform clinicians when a Variant of Uncertain Significance (VUS) has been reclassified

For Patients

  • Pre-test education on the benefits of Renasight™
  • Review Renasight™ test results, with post-test summary given to providers to add to patient charts
  • Discuss modes of inheritance and recurrence risks of genetic conditions for patients and family members

Request more information about Renasight™

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

1Natera data on file

2Groopman EE, Marasa M, Cameron-Christie S et al. Diagnostic utility of exome sequencing for kidney disease. NEJM. 2018;doi:10.1056.

icon-angle icon-bars icon-times